Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2014-10-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1517/17425255.2014.956080PMID 25196358
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications.

  2014cited by this paper
• Analgesic Efficacy and Safety of DALDA Peptide Analog Delivery to the Brain Using Oil-in-Water Nanoemulsion Formulation

  2014cited by this paper
• CNS Delivery and Pharmacokinetic Evaluations of DALDA Analgesic Peptide Analog Administered in Nano-Sized Oil-in-Water Emulsion Formulation

  2014cited by this paper
• Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.

  2014cited by this paper
• Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.

  2014cited by this paper
• Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)

  2013cited by this paper
• Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.

  2013cited by this paper
• Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.

  2013cited by this paper
• Nanotechnology for CNS delivery of bio-therapeutic agents

  2013cited by this paper
• Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery.

  2013cited by this paper
• Silver nanoparticles (AgNPs) cause degeneration of cytoskeleton and disrupt synaptic machinery of cultured cortical neurons

  2013cited by this paper
• A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.

  2013cited by this paper
• Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study.

  2013cited by this paper
• Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions

  2012cited by this paper
• Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model.

  2012cited by this paper
• Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.

  2012cited by this paper
• Oral Delivery of Peptide Drugs

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM.

  2012cited by this paper
• The TAT peptide endows PACAP with an enhanced ability to traverse bio-barriers.

  2012cited by this paper
• Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation

  2012cited by this paper
• Nanoparticle-mediated delivery of Neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of Neurotoxin

  2012cited by this paper
• Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.

  2012cited by this paper
• Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport.

  2012cited by this paper
• In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera

  2012cited by this paper
• Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.

  2012cited by this paper
• Pharmacokinetics and disposition of various drug loaded liposomes.

  2012cited by this paper
• Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery.

  2011cited by this paper
• Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.

  2011cited by this paper
• Peptides: important tools for the treatment of central nervous system disorders.

  2011cited by this paper
• PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders.

  2011cited by this paper
• Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.

  2011cited by this paper
• Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• Creatinyl amino acids—new hybrid compounds with neuroprotective activity

  2011cited by this paper
• In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain.

  2011cited by this paper
• Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80.

  2011cited by this paper
• Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.

  2011cited by this paper
• Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1.

  2011cited by this paper
• Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.

  2011cited by this paper
• Topical Nerve Growth Factor as a Visual Rescue Strategy in Pediatric Optic Gliomas

  2011cited by this paper
• Drug Transport and Metabolism in the Blood–Brain Barrier

  2011cited by this paper
• Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.

  2011cited by this paper
• Intranasal Delivery of Human β-Amyloid Peptide in Rats: Effective Brain Targeting

  2010cited by this paper
• CNS delivery of l-dopa by a new hybrid glutathione–methionine peptidomimetic prodrug

  2010cited by this paper
• ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

  2010influential reference
• Intranasal Delivery—Modification of Drug Metabolism and Brain Disposition

  2010cited by this paper
• Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging, and Diagnosis

  2010cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• Delivery of NGF to the Brain: Intranasal versus Ocular Administration in Anti-NGF Transgenic Mice

  2009cited by this paper
• Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases

  2009cited by this paper
• New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules.

  2009cited by this paper
• Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles

  2009cited by this paper
• Nanoparticles for direct nose-to-brain delivery of drugs.

  2009cited by this paper
• A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.

  2008cited by this paper
• Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier.

  2008cited by this paper
• Drug delivery systems - an overview.

  2008cited by this paper
• Peptide transporters and their roles in physiological processes and drug disposition

  2008cited by this paper
• Peptide-based drug design: here and now.

  2008cited by this paper
• Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.

  2008cited by this paper
• Drug Targeting to the Brain

  2007cited by this paper
• Brain Drug Development and Brain Drug Targeting

  2007cited by this paper
• Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.

  2007cited by this paper
• Supply and Demand in Cerebral Energy Metabolism: The Role of Nutrient Transporters

  2007cited by this paper
• Can Nasal Drug Delivery Bypass the Blood-Brain Barrier?

  2007cited by this paper
• CNS drug delivery: Opioid peptides and the blood-brain barrier

  2006cited by this paper
• Resolving the nanoparticles paradox.

  2006cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• In vivo evaluation of a nasal insulin delivery system based on thiolated chitosan.

  2006cited by this paper
• Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.

  2005cited by this paper
• Engineering of nanoemulsions for drug delivery.

  2005cited by this paper
• Human growth hormone and insulin-like growth factor-I inhibit erythropoietin secretion from the kidneys of adult rats.

  2005cited by this paper
• Oral delivery of peptide drugs: barriers and developments.

  2005cited by this paper
• Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat.

  2005cited by this paper
• Nanomedicine: current status and future prospects

  2005cited by this paper
• Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy

  2004cited by this paper
• Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.

  2004cited by this paper
• Role of PEPT2 in the Choroid Plexus Uptake of Glycylsarcosine and 5-Aminolevulinic Acid: Studies in Wild-Type and Null Mice

  2004cited by this paper
• Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase

  2004cited by this paper
• Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease

  2004cited by this paper
• Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

  2004cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Translocation of Inhaled Ultrafine Particles to the Brain

  2004cited by this paper
• Drug Metabolism in the Nasal Mucosa

  2004cited by this paper
• Oral peptide and protein delivery: unfulfilled promises?

  2003cited by this paper
• Nasal drug delivery--possibilities, problems and solutions.

  2003cited by this paper
• Accumulation of Porcine Insulin in the Rat Brain and Cerebrospinal Fluid Following Ocular Application

  2003cited by this paper
• APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response*

  2003cited by this paper
• A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation.

  2003cited by this paper
• Modifying peptide properties by prodrug design for enhanced transport into the CNS.

  2003cited by this paper
• Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond.

  2003cited by this paper
• Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles

  2003cited by this paper
• Drug delivery to the central nervous system: a review.

  2003cited by this paper
• Protection against ischemic brain injury by protein therapeutics

  2002cited by this paper
• Brain drug targeting: Linker strategies: the engineering of multifunctional drug formulations

  2001cited by this paper
• Long-circulating and target-specific nanoparticles: theory to practice.

  2001cited by this paper
• Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1).

  2001cited by this paper
• Drug delivery to damaged brain.

  2001cited by this paper
• Drug delivery for posterior segment eye disease.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper

• Food-Derived Peptides: Beneficial CNS Effects and Cross-BBB Transmission Strategies.

  2023cites this paper
• Systematic Designing and Optimization of Polymeric Nanoparticles Using Central Composite Design: A Novel Approach for Nose-to-Brain Delivery of Donepezil Hydrochloride

  2023cites this paper
• A Comprehensive Review on Nanomedicine: Promising approach for treatment of brain tumor through intranasal administration.

  2022cites this paper
• On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles

  2022cites this paper
• Particulate carriers for nose-to-brain delivery

  2021cites this paper
• Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease.

  2020cites this paper
• Sensitive method for endotoxin determination in nanomedicinal product samples.

  2019cites this paper
• Efficient brain uptake and distribution of an expanded CAG RNA inhibitor DB213 via intranasal administration

  2019cites this paper
• Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery

  2019cites this paper
• Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration.

  2018cites this paper
• Polymer Nanoparticles as Smart Carriers for the Enhanced Release of Therapeutic Agents to the CNS.

  2016cites this paper
• Pharmacokinetics and brain uptake of HIV-1 replication inhibitor DB213 in Sprague-Dawley rats.

  2016cites this paper
• A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements

  2016cites this paper
• Study of the potential of peptide amphiphile micelles as nanocarriers for drug delivery into the brain

  2015cites this paper